Abstract:Neutrophils frequently infiltrate solid tumors, where they can have pro-tumor effects that significantly worsen clinical outcomes for many types of cancer. However, our understanding of how neutrophils benefit tumors is far from complete. In the tumor microenvironment, neutrophils encounter myriad signals that stimulate the release of myeloperoxidase (MPO), a peroxidase that has commonly been thought to be cytotoxic due to its catalytic generation of the highly reactive oxygen species, hypochlorous acid. However, in this study we show that exogenous MPO, such as that released by neutrophils into the tumor microenvironment, acts as a tumor-promoter. Using fluorescent microscopy of cultured tumor cells, we show that MPO treatment significantly enhances chemoresistance of cells from every tumor model tested, including breast, ovarian, prostate, and bladder cancers, among others. Cells treated with both MPO and doxorubicin have a more than 2-fold increase in EC50 compared to cells treated with doxorubicin alone. Many cell types also show significant resistance to other chemotherapies, such as docetaxel, cisplatin, and ribociclib. Using transwell migration and Matrigel invasion assays, we showed that MPO-treated tumor cells have increased migration and invasion, indicating that MPO may also function to increase tumor metastasis. To determine whether MPO's enzymatic activity is necessary for its pro-tumor effects, we generated an enzymatically dead mutant, MPO(M409V). We found that MPO(M409V) did not enhance chemoresistance. Additionally, cells treated with MPO(M409V) did not show increases in migration or invasion above untreated cells. We also wanted to understand how MPO's localization affected tumor cells in these assays. We showed that wild type MPO binds and is rapidly internalized into tumor cells, and, by 14 hours, localizes exclusively to the nucleus. Previous studies have suggested that MPO internalization is due to a dense patch of basic residues on the surface of MPO. Therefore, we generated a charge-mutant MPO (MPO(R559E/R603A/R622E/K652E/R653P)), where 5 residues in the "basic patch" were changed to acidic or neutral amino acids. Immunocytochemistry with the charge-mutant MPO showed decreased intracellular localization, with no nuclear staining. When we tested the effects of the charge-mutant MPO on chemoresistance, migration, and invasion, we found no significant change compared to cells with MPO(M409V) or no MPO treatments. Together, these data show that MPO-treatment of cells increases chemoresistance, migration, and invasion in a manner that is dependent on MPO catalytic activity, electrostatic charge, and subcellular localization. Finally, we used immunocytochemistry on human tumor cells extracted by fine needle aspiration to show that MPO is found in human tumor cells, indicating that MPO could be a clinically-relevant tumor promoter. Citation Format: Rita P Loudermilk, James A Wells. Tumor-localized myeloperoxidase enhances tumor chemoresistance, migration, and invason. [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A053.

Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy

Abstract A053: Tumor-localized myeloperoxidase enhances tumor chemoresistance, migration, and invason.

Anti-PD-L1 treatment to enhance the response of glioblastoma to radiation and produce long-term survival in mice.

Abstract 4989: Targeting IL-1β mitigates radiation induced MDSC expansion & improves survival in glioblastoma

Myeloperoxidase Molecular MRI Reveals Synergistic Combination Therapy in Murine Experimental Autoimmune Neuroinflammation.

Sublethal dose of irradiation enhances invasion of malignant glioma cells through p53-MMP 2 pathway in U87MG mouse brain tumor model

Unlocking the Potential of Ultra-High Dose Fractionated Radiation for Effective Treatment of Glioblastoma in Mice

Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model

RDNA-05. RADIOTHERAPY PROMOTES ONCOPROGRESSIVE CROSSTALK BETWEEN GLIOBLASTOMA TUMOR CELLS AND M2 MACROPHAGES VIA THE NLRP3 INFLAMMASOME PATHWAY

PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation

Host Mediated Inflammatory Influence on Glioblastoma Multiforme Recurrence Following High-Dose Ionizing Radiation

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma

Molecular Immuno-Imaging Improves Tumor Detection in Head and Neck Cancer.

TMIC-47. SINGLE-CELL TRANSCRIPTOMICS REVEALS ANTITUMOR IMMUNE RESPONSES OF PROTON TREATMENT IN GLIOBLASTOMA

Microglia and glioblastoma heterocellular interplay sustains tumour growth and proliferation as an off‐target effect of radiotherapy

205 Microglia-Mediated Survival Outcomes in Preoperative Radiation for Glioblastoma: Insights From a Preclinical Model

Abstract 2029: Investigation of anti-tumor activity of porcine myeloperoxidase for urothelial carcinoma of the bladder

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

Dissecting anti-tumor immunity in glioblastoma

M2 isoform of pyruvate kinase rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance

Dnar-16. Targeting Apobec Cytidine Deaminases To Enhance Radiosensitivity In Glioma